Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Reactivation of a TAL1 progenitor cell enhancer region by non-coding somatic variants in T-lineage acute lymphoblastic leukemia.

bioRxiv : the preprint server for biology·2026
Same author

Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation.

Cell reports·2026
Same author

Multitargeted Reduction of Inflammation and Atherosclerosis in <i>Tet2</i> -deficient CHIP via XPO1 Inhibition and Atf3 restoration.

bioRxiv : the preprint server for biology·2025
Same author

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma.

bioRxiv : the preprint server for biology·2025
Same author

Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation.

Cell reports·2025
Same author

Accurate Measurement of Cell Number-Normalized Differential Gene Expression in Cells Treated With Retinoic Acid.

Bio-protocol·2024
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
查看所有相关文章

相关实验视频

Updated: Jul 6, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

急性淋巴细胞白血病急性淋巴细胞白血病.

Ching-Hon Pui1, Leslie L Robison, A Thomas Look

  • 1Department of Oncology, St Jude Children's Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105, USA. ching-hon.pui@stjude.org

Lancet (London, England)
|March 25, 2008
PubMed
概括
此摘要是机器生成的。

急性淋巴细胞白血病 (ALL) 影响儿童和成人. 研究重点是针对性疗法和改进的治疗方法,以提高治愈率和减少副作用.

更多相关视频

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

相关实验视频

Last Updated: Jul 6, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

科学领域:

  • 血液学 血液学 血液学
  • 儿科瘤学 儿科瘤学
  • 分子生物学分子生物学

背景情况:

  • 急性淋巴细胞白血病 (ALL) 是儿童和成人常见的一种淋巴原生细胞恶性瘤.
  • 目前的治疗方法在儿童中达到80%以上的治愈率,但具有显著的毒性.
  • 了解ALL的病理生物学对于开发更少毒性,更有效的疗法至关重要.

研究的目的:

  • 探索针对ALL的创新治疗策略,以保持生存率的提高,同时尽量减少副作用.
  • 研究基于白血病细胞遗传缺陷的分子向疗法的潜力.
  • 提高成人和高风险儿科ALL亚组的治愈率.

主要方法:

  • 对当前治疗结果和儿童和成人ALL中毒性的综述.
  • 分析新兴的分子技术及其在ALL病理生物学中的应用.
  • 目前正在进行的研究调查ALL的起源,风险因素和新的治疗方案.

主要成果:

  • 高治愈率 (>80%) 在儿童ALL中可通过密集治疗方案实现.
  • 分子进步为针对特定遗传缺陷的向治疗提供了潜力.
  • 成人和高风险儿科ALL种群的治愈率仍然低于最佳.

结论:

  • 向疗法有望通过解决特定遗传缺陷来彻底改变ALL的治疗方法.
  • 需要进一步的研究来优化成人和高风险儿科ALL的治疗.
  • 与降低毒性平衡疗效是未来ALL治疗策略的关键目标.